Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Activiomics Extends Agreement with Kyowa Hakko Kirin

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Activiomics announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme.

Activiomics will apply its novel TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform to elucidate signalling mechanisms generated by lead compounds supplied by KHK in relevant cell-based systems. This collaboration falls within Activiomics’ strategic partnership with BioFocus.

Activiomics applies innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity resulting from drug administration and/or disease progression. The company is utilising its technology for the discovery and clinical validation of novel prognostic and predictive biomarkers as well as to provide high-value drug mode of action information for the pharmaceutical and biotechnology industry.

“We have been impressed with the results from the initial stages of our partnership with Activiomics and look forward to working with them on this new programme,” said Hiroshi Okazaki, Ph.D., Managing Officer and Vice President, Head, Research Division, Head, Fuji Research Park at Kyowa Hakko Kirin.

Dr Kevin FitzGerald, CEO of Activiomics, said: “We are delighted to have signed a new contract with Kyowa Hakko Kirin which follows on from a previous successful study. The extension of the partnership is a strong endorsement of the quality and quantity of information that can be generated using our technology platform. We are also grateful to the invaluable support from BioFocus in establishing this collaboration.”

Dr Chris Newton, Managing Director of BioFocus, commented: “We are delighted that the capabilities of our strategic partner, Activiomics, has captured the interest of our client Kyowa Hakko Kirin, and look forward to further synergies from  our alliance with Activiomics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Activiomics Announces Appointment of Non-Executive Chairman
Dr Trevor Nicholls appointed as Non-executive chairman.
Wednesday, March 28, 2012
Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!